Cargando…

Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz

PURPOSE: To treat malaria, HIV-infected patients normally receive artemether (80 mg twice daily) concurrently with antiretroviral therapy and drug-drug interactions can potentially occur. Artemether is a substrate of CYP3A4 and CYP2B6, antiretrovirals such as efavirenz induce these enzymes and have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siccardi, Marco, Olagunju, Adeniyi, Seden, Kay, Ebrahimjee, Farid, Rannard, Steve, Back, David, Owen, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230487/ https://www.ncbi.nlm.nih.gov/pubmed/25505649 http://dx.doi.org/10.1186/2193-9616-1-4

Ejemplares similares

Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies
por: Atoyebi, Shakir Adeyinka, et al.
Publicado: (2019)

Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems
por: Liptrott, Neill J., et al.
Publicado: (2018)

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by CYP2B6 c.516G>T Genotypes
por: Abdullahi, Sa’ad T., et al.
Publicado: (2020)

High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily
por: Seden, Kay, et al.
Publicado: (2018)

Clinically relevant enantiomer specific R‐ and S‐praziquantel pharmacokinetic drug‐drug interactions with efavirenz and ritonavir
por: Mutiti, Chenai Sheilla, et al.
Publicado: (2021)

Towards a rational design of solid drug nanoparticles with optimised pharmacological properties
por: Siccardi, Marco, et al.
Publicado: (2016)

Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria
por: Nwogu, Jacinta N., et al.
Publicado: (2021)

Prevalence and type of drug–drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda
por: Seden, K., et al.
Publicado: (2015)

Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort
por: Kigen, Gabriel, et al.
Publicado: (2011)

Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine
por: Ali, Shabana, et al.
Publicado: (2010)

Enhanced Oral Bioavailability of Efavirenz by Solid Lipid Nanoparticles: In Vitro Drug Release and Pharmacokinetics Studies
por: Gaur, Praveen Kumar, et al.
Publicado: (2014)

Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment
por: Brasher, William P, et al.
Publicado: (2020)

CYP2B6*6 Genotype Specific Differences in Artemether‐Lumefantrine Disposition in Healthy Volunteers
por: Abdullahi, Sa'ad T., et al.
Publicado: (2019)

Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry
por: Olagunju, Adeniyi, et al.
Publicado: (2022)

Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies
por: Hobson, James J., et al.
Publicado: (2019)

Pharmacokinetics and Drug‐Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping
por: Gausi, Kamunkhwala, et al.
Publicado: (2020)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz
por: Chetty, Manoranjenni, et al.
Publicado: (2018)

Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults
por: Lamorde, Mohammed, et al.
Publicado: (2012)

Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria
por: Nwogu, Jacinta N., et al.
Publicado: (2022)

Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy
por: Banda, Clifford G., et al.
Publicado: (2018)

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection
por: Seden, Kay, et al.
Publicado: (2017)

Giant annular lichenoid drug eruption caused by efavirenz therapy
por: Baumrin, Emily, et al.
Publicado: (2018)

The Antiviral Drug Efavirenz in Breast Cancer Stem Cell Therapy
por: Chiou, Pey-Tsyr, et al.
Publicado: (2021)

A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab
por: Stader, Felix, et al.
Publicado: (2019)

Evaluating pharmacist involvement in HIV outpatient clinics: can medication histories, drug interaction checks and adherence assessments add benefit?
por: Seden, K, et al.
Publicado: (2010)

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
por: Walimbwa, Stephen I., et al.
Publicado: (2019)

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

From chloroquine to artemether-lumefantrine: the process of drug policy change in Zambia
por: Sipilanyambe, Naawa, et al.
Publicado: (2008)

Olfactory drug delivery of artemether-curcumin combination for management of cerebral malaria
por: Jain, Kunal, et al.
Publicado: (2012)

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter
por: Moss, Darren M., et al.
Publicado: (2015)

Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
por: Hoglund, Richard M, et al.
Publicado: (2015)

Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study
por: Buzibye, Allan, et al.
Publicado: (2023)

Albumin nanoparticles coated with polysorbate 80 as a novel drug carrier for the delivery of antiretroviral drug—Efavirenz
por: Jenita, Josephine Leno, et al.
Publicado: (2014)

Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother–infant pairs
por: Waitt, Catriona, et al.
Publicado: (2018)

Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial
por: Olagunju, Adeniyi, et al.
Publicado: (2021)

Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients
por: Yimer, Getnet, et al.
Publicado: (2011)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
por: Rodriguez-Vera, Leyanis, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a5e35g2ip4ff8dmid4pd9f3p4v